<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00440531</url>
  </required_header>
  <id_info>
    <org_study_id>V232-059</org_study_id>
    <secondary_id>2007_516</secondary_id>
    <nct_id>NCT00440531</nct_id>
  </id_info>
  <brief_title>Study of Recombinant Modified Process Hepatitis B Vaccine in Older Adults (V232-059)(COMPLETED)</brief_title>
  <official_title>A Study in Healthy Adults of the Safety, Tolerability, and Immunogenicity of Recombinant Hepatitis B Vaccine Manufactured With a Modified Process</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine if there is an improvement in the immune response
      of older adults over 50 years of age using a modified process hepatitis B vaccine and a
      currently licensed hepatitis B vaccine (RECOMBIVAX HB™).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Seroresponders to the Modified Process Hepatitis B Vaccine and RECOMBIVAX HB™ (Currently Licensed Vaccine)</measure>
    <time_frame>7 months (1 month after third vaccination)</time_frame>
    <description>The number of participants as measured by the seroprotection rate (anti-hepatitis B surface antibodies greater than or equal to 10 mIU/mL). Anti-HBs (Antibodies against hepatitis B surface antigen) titers were measured from blood samples taken at Day 1 (prior to the first vaccination) and at Month 7 (1 month after the third vaccination).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Number of Seroresponders to ENGERIX-B™ (Currently Licensed Vaccine)</measure>
    <time_frame>7 months (1 month after third vaccination)</time_frame>
    <description>The number of participants as measured by the seroprotection rate (anti-hepatitis B surface antibodies greater than or equal to 10 mIU/mL). Anti-HBs (Antibodies against hepatitis B surface antigen) titers were measured from blood samples taken at Day 1 (prior to the first vaccination) and at Month 7 (1 month after the third vaccination).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Total Number of Participants With One or More Injection-site Adverse Experiences</measure>
    <time_frame>Days 1-5 After Any Vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Total Number of Participants With a Maximum Temperature &gt;=100.0F/37.8C</measure>
    <time_frame>Day 1-5 After Vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Total Number of Participants With Serious Vaccine-Related Clinical Adverse Experiences</measure>
    <time_frame>During Entire Study Period (from first vaccination until the participant completes or discontinues: up to 7 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">540</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>RECOMBIVAX HB™</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Modified Process Hepatitis B Vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ENGERIX-B™</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: RECOMBIVAX HB™ Hepatitis B Vaccine (Recombinant)</intervention_name>
    <description>RECOMBIVAX HB™ (currently licensed product) given IM (Intramuscular) in 3 doses of 10 mcg (micrograms)/1.0 mL each over 6 months.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: Modified Process Hepatitis B Vaccine (Experimental)</intervention_name>
    <description>Modified Process Hepatitis B Vaccine (Experimental) given IM (Intramuscular) in 3 doses of 10 mcg (micrograms)/1.0 mL each over 6 months.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: ENGERIX-B™ (currently licensed product)</intervention_name>
    <description>ENGERIX-B™ given IM (Intramuscular) in 3 doses of 20 mcg (micrograms)/1.0 mL each over 6 months.</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female older adults greater than or equal to 50 years of age

        Exclusion Criteria:

          -  Any adult with a history of previous hepatitis B infection

          -  A history of vaccination with any hepatitis B vaccine

          -  Recent (&lt;72 hours) history of febrile illness (oral temperature =37.8ºC/=100.0ºF)

          -  Known or suspected hypersensitivity to any component of RECOMBIVAX HB™ or ENGERIX-B™
             (e.g., aluminum, yeast)

          -  Recent administration (within 3 months prior to first injection with the study
             vaccine) of hepatitis B immune globulin (HBIG), serum immune globulin, or any other
             blood-derived product

          -  Receipt of licensed inactivated vaccines within 14 days prior to first injection with
             the study vaccine

          -  Receipt of licensed live virus vaccines within the 30 days prior to injection with the
             study vaccine

          -  Receipt of investigational drugs or other investigational vaccines within 3 months
             prior to first injection with the study vaccine

          -  Known or suspected impairment of immunologic function or recent use of
             immunomodulatory medications (e.g., systemic corticosteroids). Does not include
             topical and inhaled steroids

          -  Pregnant women, nursing mothers, and women planning to become pregnant within the
             study period

          -  Any condition that, in the opinion of the investigator, might interfere with the
             evaluation of the study objectives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>MedWatch - FDA maintained medical product safety Information</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>Merck: Patient &amp; Caregiver U.S. Product Web Site</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2007</study_first_submitted>
  <study_first_submitted_qc>February 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2007</study_first_posted>
  <results_first_submitted>November 11, 2008</results_first_submitted>
  <results_first_submitted_qc>February 27, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 31, 2009</results_first_posted>
  <last_update_submitted>March 16, 2017</last_update_submitted>
  <last_update_submitted_qc>March 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>27-Nov-2006 (First Participant Enrolled in Study) to 26-Nov-2007 (Last Participant had their Last Visit). This study was conducted at 22 sites: 10 in Canada, 2 in Denmark, 5 in Sweden, and 5 in the United Kingdom.</recruitment_details>
      <pre_assignment_details>In the Modified Process group, 2 participants were randomized but not vaccinated: 1 participant withdrew consent, and 1 participant had an SAE (Serious Adverse Experience) of hypertension prior to vaccination.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Modified Process Hepatitis B Vaccine</title>
          <description>Modified Process Hepatitis B Vaccine, 10 µg (micrograms)</description>
        </group>
        <group group_id="P2">
          <title>RECOMBIVAX-HB™</title>
          <description>RECOMBIVAX-HB™, 10 µg (micrograms)</description>
        </group>
        <group group_id="P3">
          <title>ENGERIX-B™</title>
          <description>ENGERIX-B™, 20 µg (micrograms)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="185"/>
                <participants group_id="P2" count="183"/>
                <participants group_id="P3" count="172"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination 1</title>
              <participants_list>
                <participants group_id="P1" count="183"/>
                <participants group_id="P2" count="183"/>
                <participants group_id="P3" count="172"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination 2</title>
              <participants_list>
                <participants group_id="P1" count="181"/>
                <participants group_id="P2" count="182"/>
                <participants group_id="P3" count="171"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination 3</title>
              <participants_list>
                <participants group_id="P1" count="176"/>
                <participants group_id="P2" count="178"/>
                <participants group_id="P3" count="166"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="175"/>
                <participants group_id="P2" count="178"/>
                <participants group_id="P3" count="165"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>see pre-assignment details</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Modified Process Hepatitis B Vaccine</title>
          <description>Modified Process Hepatitis B Vaccine, 10 µg (micrograms)</description>
        </group>
        <group group_id="B2">
          <title>RECOMBIVAX-HB™</title>
          <description>RECOMBIVAX-HB™, 10 µg (micrograms)</description>
        </group>
        <group group_id="B3">
          <title>ENGERIX-B™</title>
          <description>ENGERIX-B™, 20 µg (micrograms)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="183"/>
            <count group_id="B2" value="183"/>
            <count group_id="B3" value="172"/>
            <count group_id="B4" value="538"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.3" spread="7.9"/>
                    <measurement group_id="B2" value="60.4" spread="7.6"/>
                    <measurement group_id="B3" value="59.8" spread="6.5"/>
                    <measurement group_id="B4" value="60.2" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="73"/>
                    <measurement group_id="B4" value="260"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="99"/>
                    <measurement group_id="B4" value="278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Seroresponders to the Modified Process Hepatitis B Vaccine and RECOMBIVAX HB™ (Currently Licensed Vaccine)</title>
        <description>The number of participants as measured by the seroprotection rate (anti-hepatitis B surface antibodies greater than or equal to 10 mIU/mL). Anti-HBs (Antibodies against hepatitis B surface antigen) titers were measured from blood samples taken at Day 1 (prior to the first vaccination) and at Month 7 (1 month after the third vaccination).</description>
        <time_frame>7 months (1 month after third vaccination)</time_frame>
        <population>Per-protocol Population. The Per-protocol Population is defined as the participants that were able to complete the study as defined by the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Modified Process Hepatitis B Vaccine</title>
            <description>Modified Process Hepatitis B Vaccine, 10 µg (micrograms)</description>
          </group>
          <group group_id="O2">
            <title>RECOMBIVAX-HB™</title>
            <description>RECOMBIVAX-HB™, 10 µg (micrograms)</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Seroresponders to the Modified Process Hepatitis B Vaccine and RECOMBIVAX HB™ (Currently Licensed Vaccine)</title>
          <description>The number of participants as measured by the seroprotection rate (anti-hepatitis B surface antibodies greater than or equal to 10 mIU/mL). Anti-HBs (Antibodies against hepatitis B surface antigen) titers were measured from blood samples taken at Day 1 (prior to the first vaccination) and at Month 7 (1 month after the third vaccination).</description>
          <population>Per-protocol Population. The Per-protocol Population is defined as the participants that were able to complete the study as defined by the protocol.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>No hypothesis is being tested. The purpose of the primary analysis is to estimate the seroprotection rate (percentage of subjects with anti-HBs &gt;=10mIU/mL) in each group at 1 month post vaccination 3, among subjects who were seronegative at baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>single-group percentage</param_type>
            <param_value>75.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>68</ci_lower_limit>
            <ci_upper_limit>82.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No hypothesis is being tested. The purpose of the primary analysis is to estimate the seroprotection rate (percentage of subjects with anti-HBs &gt;=10mIU/mL) in each group at 1 month post vaccination 3, among subjects who were seronegative at baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>single-group percentage</param_type>
            <param_value>68</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>59.80</ci_lower_limit>
            <ci_upper_limit>75.50</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Seroresponders to ENGERIX-B™ (Currently Licensed Vaccine)</title>
        <description>The number of participants as measured by the seroprotection rate (anti-hepatitis B surface antibodies greater than or equal to 10 mIU/mL). Anti-HBs (Antibodies against hepatitis B surface antigen) titers were measured from blood samples taken at Day 1 (prior to the first vaccination) and at Month 7 (1 month after the third vaccination).</description>
        <time_frame>7 months (1 month after third vaccination)</time_frame>
        <population>Per-protocol Population. The Per-protocol Population is defined as the participants that were able to complete the study as defined by the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>ENGERIX-B™</title>
            <description>ENGERIX-B™, 20 µg (micrograms)</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Seroresponders to ENGERIX-B™ (Currently Licensed Vaccine)</title>
          <description>The number of participants as measured by the seroprotection rate (anti-hepatitis B surface antibodies greater than or equal to 10 mIU/mL). Anti-HBs (Antibodies against hepatitis B surface antigen) titers were measured from blood samples taken at Day 1 (prior to the first vaccination) and at Month 7 (1 month after the third vaccination).</description>
          <population>Per-protocol Population. The Per-protocol Population is defined as the participants that were able to complete the study as defined by the protocol.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>No hypothesis is being tested. The purpose of the secondary analysis is to estimate the seroprotection rate (percentage of subjects with anti-HBs &gt;=10mIU/mL) for ENGERIX-B™ at 1 month post vaccination 3, among subjects who were seronegative at baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Single-Group Percentage</param_type>
            <param_value>84</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>77</ci_lower_limit>
            <ci_upper_limit>89.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Total Number of Participants With One or More Injection-site Adverse Experiences</title>
        <time_frame>Days 1-5 After Any Vaccination</time_frame>
        <population>Safety Analysis Set – defined as all participants who received at least one injection of vaccine and who had a safety follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Modified Process Hepatitis B Vaccine</title>
            <description>Modified Process Hepatitis B Vaccine, 10 µg (micrograms)</description>
          </group>
          <group group_id="O2">
            <title>RECOMBIVAX-HB™</title>
            <description>RECOMBIVAX-HB™, 10 µg (micrograms)</description>
          </group>
          <group group_id="O3">
            <title>ENGERIX-B™</title>
            <description>ENGERIX-B™, 20 µg (micrograms)</description>
          </group>
        </group_list>
        <measure>
          <title>The Total Number of Participants With One or More Injection-site Adverse Experiences</title>
          <population>Safety Analysis Set – defined as all participants who received at least one injection of vaccine and who had a safety follow-up.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="183"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="115"/>
                    <measurement group_id="O3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Total Number of Participants With a Maximum Temperature &gt;=100.0F/37.8C</title>
        <time_frame>Day 1-5 After Vaccination</time_frame>
        <population>Safety Analysis Set - defined as all participants who received at least one injection of vaccine and who had a safety follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Modified Process Hepatitis B Vaccine</title>
            <description>Modified Process Hepatitis B Vaccine, 10 µg (micrograms)</description>
          </group>
          <group group_id="O2">
            <title>RECOMBIVAX-HB™</title>
            <description>RECOMBIVAX-HB™, 10 µg (micrograms)</description>
          </group>
          <group group_id="O3">
            <title>ENGERIX-B™</title>
            <description>ENGERIX-B™, 20 µg (micrograms)</description>
          </group>
        </group_list>
        <measure>
          <title>The Total Number of Participants With a Maximum Temperature &gt;=100.0F/37.8C</title>
          <population>Safety Analysis Set - defined as all participants who received at least one injection of vaccine and who had a safety follow-up.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="183"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Total Number of Participants With Serious Vaccine-Related Clinical Adverse Experiences</title>
        <time_frame>During Entire Study Period (from first vaccination until the participant completes or discontinues: up to 7 months)</time_frame>
        <population>Safety Analysis Set – defined as all participants who received at least one injection of vaccine and who had a safety follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Modified Process Hepatitis B Vaccine</title>
            <description>Modified Process Hepatitis B Vaccine, 10 µg (micrograms)</description>
          </group>
          <group group_id="O2">
            <title>RECOMBIVAX-HB™</title>
            <description>RECOMBIVAX-HB™, 10 µg (micrograms)</description>
          </group>
          <group group_id="O3">
            <title>ENGERIX-B™</title>
            <description>ENGERIX-B™, 20 µg (micrograms)</description>
          </group>
        </group_list>
        <measure>
          <title>The Total Number of Participants With Serious Vaccine-Related Clinical Adverse Experiences</title>
          <population>Safety Analysis Set – defined as all participants who received at least one injection of vaccine and who had a safety follow-up.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="183"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Clinical and Quantitative Sciences</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

